Mar 19, 2024 / 08:30PM GMT
Operator
Greetings, and welcome to Taysha Gene Therapies fourth quarter and full year 2023 earnings call. (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce Hayleigh Collins, Director, Head of Corporate Communications and Investor Relations. Thank you, you may begin.
Hayleigh Collins - Taysha Gene Therapies Inc - Director, Head of Corporate Communications and Investor Relations
Thank you. Good afternoon, and welcome to Taysha's full year 2023 financial results and corporate update conference call. Earlier today, we issued a press release announcing financial results for the full year ended December 31, 2023. A copy of this press release is available on the Company's website and through our SEC filings.
Joining me on today's call are Sean Nolan, Taysha's CEO; Sukumar Nagendran, President and Head of R&D; and Kamran Alam, Chief Financial Officer. We will hold a question and answer session following our prepared remarks.
Please note that on today's call, we will be making forward
Q4 2023 Taysha Gene Therapies Inc Earnings Call Transcript
Mar 20, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers